Show simple item record

dc.contributor.authorDoshi, Peter
dc.date.accessioned2021-05-18T16:31:10Z
dc.date.available2021-05-18T16:31:10Z
dc.date.issued2021-05-18
dc.identifier.urihttp://hdl.handle.net/10713/15669
dc.descriptionPeter Doshi questions the rush to seek FDA approval for the COVID-19 vaccines currently being administered under the FDA's "Emergency Use Authorization"en_US
dc.description.urihttps://doi.org/10.1136/bmj.n1244en_US
dc.language.isoenen_US
dc.publisherBMJ Publishing Groupen_US
dc.relation.ispartofBMJen_US
dc.rights.urihttp://www.bmj.com/company/legal-information/terms-conditions/legal-information/tdm-licencepolicy
dc.subject.lcshUnited States. Food and Drug Administrationen_US
dc.subject.meshCOVID-19 Vaccinesen_US
dc.subject.meshDrug Approvalen_US
dc.titleCovid-19 vaccines: In the rush for regulatory approval, do we need more data?en_US
dc.typeArticleen_US
dc.identifier.doi10.1136/bmj.n1244
dc.source.journaltitleBMJ
dc.source.beginpagen1244


This item appears in the following Collection(s)

Show simple item record